Revelation Biosciences, Inc., (REVB): Price and Financial Metrics
REVB Price/Volume Stats
| Current price | $0.82 | 52-week high | $60.80 |
| Prev. close | $0.88 | 52-week low | $0.77 |
| Day low | $0.80 | Volume | 1,264,900 |
| Day high | $0.89 | Avg. volume | 696,153 |
| 50-day MA | $2.66 | Dividend yield | N/A |
| 200-day MA | $7.92 | Market Cap | 785.66K |
REVB Stock Price Chart Interactive Chart >
Revelation Biosciences, Inc., (REVB) Company Bio
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.
REVB Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
REVB Price Returns
| 1-mo | -71.68% |
| 3-mo | -76.50% |
| 6-mo | -88.35% |
| 1-year | -97.68% |
| 3-year | -99.99% |
| 5-year | N/A |
| YTD | -88.88% |
| 2024 | -96.93% |
| 2023 | -92.47% |
| 2022 | -98.14% |
| 2021 | 1.49% |
| 2020 | N/A |